Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2001-04-05
2004-10-19
Eyler, Yvonne (Department: 1646)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C436S501000
Reexamination Certificate
active
06806054
ABSTRACT:
FIELD OF THE INVENTION
The invention disclosed in this patent document relates to transmembrane receptors, and more particularly to G protein-coupled receptors for which the endogenous ligand has been identified (“known GPCR”), and specifically to known GPCRs that have been altered to establish or enhance constitutive activity of the receptor. Most preferably, the altered GPCRs are used for the direct identification of candidate compounds as receptor agonists, inverse agonists or partial agonists for use as therapeutic agents.
BACKGROUND OF THE INVENTION
Although a number of receptor classes exist in humans, by far the most abundant and therapeutically relevant is represented by the G protein-coupled receptor (GPCR or GPCRs) class. It is estimated that there are some 100,000 genes within the human genome, and of these, approximately 2%, or 2,000 genes, are estimated to code for GPCRs. Receptors, including GPCRs, for which the endogenous ligand has been identified are referred to as “known” receptors, while receptors for which the endogenous ligand has not been identified are referred to as “orphan” receptors. GPCRs represent an important area for the development of pharmaceutical products: from approximately 20 of the 100 known GPCRs, 60% of all prescription pharmaceuticals have been developed.
GPCRs share a common structural motif. (All these receptors have seven sequences of between 22 to 24 hydrophobic amino acids that form seven alpha helices, each of which spans the membrane (each span is identified by number, i.e., transmembrane-1 (TM-1), transmembrane-2 (TM-2), etc.). The transmembrane helices are joined by strands of amino acids between transmembrane-2 and transmembrane-3, transmembrane-4 and transmembrane-5, and transmembrane-6 and transmembrane-7 on the exterior, or “extracellular” side, of the cell membrane (these are referred to as “extracellular” regions 1, 2 and 3 (EC-1, EC-2 and EC-3), respectively). The transmembrane helices are also joined by strands of amino acids between transmembrane-1 and transmembrane-2, transmembrane-3 and transmembrane-4, and transmembrane-5 and transmembrane-6 on the interior, or “intracellular” side, of the cell membrane (these are referred to as “intracellular” regions 1, 2 and 3 (IC-1, IC-2 and IC-3), respectively). The “carboxy” (“C”) terminus of the receptor lies in the intracellular space within the cell, and the “amino” (“N”) terminus of the receptor lies in the extracellular space outside of the cell.
Generally, when an endogenous ligand binds with the receptor (often referred to as “activation” of the receptor), there is a change in the conformation of the intracellular region that allows for coupling between the intracellular region and an intracellular “G-protein.” It has been reported that GPCRs are “promiscuous” with respect to G proteins, i.e., that a GPCR can interact with more than one G protein. See, Kenakin, T., 43
Life Sciences
1095 (1988). Although other G proteins exist, currently, Gq, Gs, Gi, Gz and Go are G proteins that have been identified. Endogenous ligand-activated GPCR coupling with the G-protein begins a signaling cascade process (referred to as “signal transduction”). Under normal conditions, signal transduction ultimately results in cellular activation or cellular inhibition. It is thought that the IC-3 loop as well as the carboxy terminus of the receptor interact with the G protein.
Under physiological conditions, GPCRs exist in the cell membrane in equilibrium between two different conformations: an “inactive” state and an “active” state. A receptor in an inactive state is unable to link to the intracellular signaling transduction pathway to produce a biological response. Changing the receptor conformation to the active state allows linkage to the transduction pathway (via the G-protein) and produces a biological response.
A receptor may be stabilized in an active state by an endogenous ligand or a compound such as a drug. Recent discoveries, including but not exclusively limited to modifications to the amino acid sequence of the receptor, provide means other than endogenous ligands or drugs to promote and stabilize the receptor in the active state conformation. These means effectively stabilize the receptor in an active state by simulating the effect of an endogenous ligand binding to the receptor. Stabilization by such ligand-independent means is termed “constitutive receptor activation.”
Traditional ligand-dependent screens seek to indirectly identify compounds that antagonize the action of the ligand on the receptor in an effort to prevent ligand-induced activation of the receptor. However, such compounds, sometimes referred to as neutral-antagonists, generally would not be expected to affect the ligand-independent activity, or overactivity, of the receptor and the subsequent abnormal cellular response that can result from this overactivity. This is particularly relevant to a growing number of diseases, such as those identified in the table below, that have been linked to overactive GPCRs, because traditional neutral-antagonists will not block the abnormal ligand-independent activity of these receptors.
Background Table 1
Disease
Overactive GPCR
Schizophrenia
5-HT2A, D2
Depression
5-HT2A
Hyperthyroidism
Thyrotropin
Hypertension
Angiotensin AT1A
Asthma
Adenosine A1
Melanoma
MC-1
Retinitis Pigmentosa
Rhodopsin receptor
SUMMARY OF THE INVENTION
Disclosed herein are non-endogenous versions of endogenous, known GPCRs and uses thereof.
REFERENCES:
patent: 6107324 (2000-08-01), Behan et al.
patent: 6140509 (2000-10-01), Behan et al.
patent: 6150393 (2000-11-01), Behan et al.
patent: 6358698 (2002-03-01), Weiner et al.
patent: WO 95/00848 (1995-01-01), None
patent: WO 96/37775 (1996-11-01), None
patent: WO 98/31828 (1998-07-01), None
patent: WO 98/38217 (1998-09-01), None
patent: WO 99/52927 (1999-10-01), None
patent: WO 00/06597 (2000-02-01), None
Herrick-Davis et al. Pharmacological characterization of the constitutively activated state of the serotonin 5-HT2c receptor. Annals of the New York Academy of Sciences 861:140-145, 1998.*
Adachi, M. et al., “Cloning and characterization of cDNA encoding human a-typr endothelin receptor”,Biochem Biophys Res Commun,1991, 180(3), 1265.
Adamou, J.E. et al., “Cloning and functional characterization of the human vasoactive intestinal peptide (VIP)2 receptor”,Biochem Biophys Res Commun, 1995, 209(2), 385.
Adham, N. et al., “Cloning of another human serotonin receptor (5-HT1f): a fifth 5 HT1 receptor subtype coupled to the inhibition of adenylate cyclase”Proc Natl Acad Sci USA, 1993, 90, pp 408-412.
Ames, R. et al., “Molecular cloning and characterization of the human anaphylatoxin C3a receptor”,J. Biol Chem, 1996, 271(34), pp. 20231-20234.
Bard, J.A. et al., “Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase”,J. Biol Chem, 1993, 268(31), pp 23422-23426.
Bastien, L. et al., “Cloning functional expression and characterization of the human prostaglandin E2 receptor EP2 subtype”,J. Biol Chem, 1994, 269(16), pp 11873-11877.
Blondel, O. et al., “Cloning, expression and pharmacology of four human 5-hydroxytryptamine 4 receptor isoforms produced by alternative splicing in the carboxyl terminus”,J Neurochem, 1998, 70, pp 2252-2261.
Bonner, T.I. et al., “Cloning and expression of the human and rat m5 muscarine acetylcholine receptor genes”,Neuron, 1988, 1(5), pp. 403-410.
Chow, B.K. “Molecular cloning and functional characterization of a human secretin receptor”,Biochem Biophys Res Commun, 1995, 212(1),pp 204-211.
Claeysen, S. et al., “Novel brain specific 5-HT4 receptor splice variants show marked constitutive activity; role to the C-terminal intracellular domain”Mol Pharmacol, 1999, 5(5), pp 910-920.
Corjay, M.H. et al., “Two Distinct bombesin receptor subtypes are expressed and functional in human lung carcinoma cells”,J Biol Chem, 1991, 266, pp 18771-18779.
Dearry, A. et al., “Molecular cloning and expression of the gene for a human D1 dopamine receptor”,Nature, 1990, 347, pp 72-76.
Dearry, A. et al., “D2 dopamine receptors in t
Lehmann-Bruinsma Karin
Liaw Chen W.
Lin I-Lin
Arena Pharmaceuticals Inc.
Eyler Yvonne
Li Ruixiang
O'Connor Cozen
Straher Michael P.
LandOfFree
Non-endogenous, constitutively activated known G... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Non-endogenous, constitutively activated known G..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-endogenous, constitutively activated known G... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3319486